Pressor and renal effects of intracerebroventricularly administered angiotensins II and III in rats.
OBJECTIVE
Experiments were performed to assess the effects of intracerebroventricular (ICV) angiotensin (ANG) III on blood pressure and renal function in rats with normal and high sodium intake and to compare these effects with those produced by ICV ANG II.


METHODS
Male Sprague-Dawley rats on a normal sodium (0.3%) diet and a normal sodium diet plus 1% NaCl as drinking water were administered ANG II and ANG III ICV through a chronically implanted cannula. Blood pressure and renal clearance function responses were measured before and during peptide administrations. The effect of ICV ANG III on the renal efferent nerve activity was also evaluated.


RESULTS
ICV injections of ANG II and ANG III at 5 pmol in rats on a normal sodium diet did not significantly alter the blood pressure, but significantly increased renal plasma flow, glomerular filtration rate, urine flow, and absolute and fractional excretions of sodium and potassium. Increased doses of ANG II and III (10, 50 and 100 pmol) significantly increased blood pressure and further enhanced these renal functional indices. Central ANG-III-induced increases in blood pressure and renal functional indices were not significantly different from those produced by ANG II at each corresponding dose. The pressor and renal effects of ANG III were blunted by a specific antagonist, Ile(7)-ANG III. ICV administration of ANG III decreased the renal efferent nerve activity. In rats with dietary NaCl loading, ICV injections of ANG II and III also significantly enhanced renal function.


CONCLUSIONS
Centrally administered ANG III is as potent as ANG II in causing pressor and renal effects in rats on normal and high sodium intake. As ANG II, brain ANG III reduced renal efferent nerve activity which may be partly accounted for the augmented renal function.
Chen
C Y
CY
Department of Radiology, Military Tauyuan General Hospital, Graduate Institute of Nuclear Science, National Tsing-Hua University Hsinchu, Hualien, Taiwan, Republic of China.
Huang
W C
WC
D000804:Angiotensin II / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D000805:Angiotensin III / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D007276:Injections, Intraventricular; D007668:Kidney / Q000187:drug effects* / Q000294:innervation; D007677:Kidney Function Tests; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D012079:Renal Circulation / Q000187:drug effects; D014662:Vasoconstrictor Agents / Q000008:administration & dosage / Q000494:pharmacology*
D014662:Vasoconstrictor Agents; D000804:Angiotensin II; D000805:Angiotensin III